• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黑色素瘤转移灶中的固有免疫细胞浸润影响生存率,并与BRAFV600E突变状态相关。

Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.

作者信息

Dabrosin Nina, Sloth Juul Karen, Bæhr Georgsen Jeanette, Andrup Simon, Schmidt Henrik, Steiniche Torben, Heide Øllegaard Trine, Bønnelykke Behrndtz Louise

机构信息

Departments of Pathology.

Oncology.

出版信息

Melanoma Res. 2019 Feb;29(1):30-37. doi: 10.1097/CMR.0000000000000515.

DOI:10.1097/CMR.0000000000000515
PMID:30299387
Abstract

Little is known about the infiltrative pattern of innate immune cells in primary melanoma compared with their paired metastases and in BRAF-mutated tumors. Therefore, our aim was to characterize the inflammatory microenvironment in primary ulcerated and nonulcerated melanomas and paired metastases, to investigate the relation between inflammation and BRAF mutation in primary melanoma and paired metastases, and to evaluate the effect of the analyzed biomarkers on melanoma-specific survival. A total of 385 primary tumors and 96 paired metastases were stained with immunohistochemistry for BRAF, CD163+ macrophages, CD123+ plasmacytoid dendritic cells, CD66b+ neutrophils, and E-cadherin and estimated using objective computer-assisted image analysis. BRAF was semiquantitatively scored as either present or absent. In metastases of nonulcerated melanomas, we observed higher neutrophil (P=0.02) and macrophage (P=0.01) numbers. In the metastases of ulcerated melanomas, we found a higher number of macrophages (P<0.0001). Increase in the neutrophil numbers in the metastases was associated with poor patient survival after first relapse (hazard ratio=1.19, 95% confidence interval: 1.03-1.38, P=0.02). BRAF-positive primary tumors (P=0.02) and metastases (P=0.01) exhibited increased plasmacytoid dendritic cell numbers compared with BRAF-negative tumors. Lastly, primary melanomas in men had higher neutrophil numbers than women (P≤0.0001), and men had worse melanoma-specific survival (hazard ratio=1.52, 95% confidence interval: 1.04-2.21, P=0.03). Our data show that melanoma metastases are densely infiltrated with neutrophils, which affects survival. Our results also highlight the importance of recognizing the presence of inflammatory cells in the metastases as a prognostic marker, and that they may potentially be used to improve the precision of immunotherapy and BRAF targeted therapy.

摘要

与配对的转移灶以及BRAF突变肿瘤相比,原发性黑色素瘤中固有免疫细胞的浸润模式鲜为人知。因此,我们的目的是对原发性溃疡性和非溃疡性黑色素瘤及其配对转移灶中的炎性微环境进行特征描述,研究原发性黑色素瘤及其配对转移灶中炎症与BRAF突变之间的关系,并评估所分析的生物标志物对黑色素瘤特异性生存的影响。总共385例原发性肿瘤和96例配对转移灶通过免疫组织化学方法进行BRAF、CD163+巨噬细胞、CD123+浆细胞样树突状细胞、CD66b+中性粒细胞和E-钙黏蛋白染色,并使用客观的计算机辅助图像分析进行评估。BRAF进行半定量评分,分为存在或不存在。在非溃疡性黑色素瘤的转移灶中,我们观察到中性粒细胞(P=0.02)和巨噬细胞(P=0.01)数量较多。在溃疡性黑色素瘤的转移灶中,我们发现巨噬细胞数量较多(P<0.0001)。转移灶中中性粒细胞数量的增加与首次复发后患者的不良生存相关(风险比=1.19,95%置信区间:1.03-1.38,P=0.02)。与BRAF阴性肿瘤相比,BRAF阳性的原发性肿瘤(P=0.02)和转移灶(P=0.01)表现出浆细胞样树突状细胞数量增加。最后,男性原发性黑色素瘤中的中性粒细胞数量高于女性(P≤0.0001),且男性的黑色素瘤特异性生存率较差(风险比=1.52,95%置信区间:1.04-2.21,P=0.03)。我们的数据表明,黑色素瘤转移灶中密集浸润有中性粒细胞,这影响生存。我们的结果还强调了识别转移灶中炎性细胞的存在作为预后标志物的重要性,并且它们可能潜在地用于提高免疫治疗和BRAF靶向治疗的精准度。

相似文献

1
Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.黑色素瘤转移灶中的固有免疫细胞浸润影响生存率,并与BRAFV600E突变状态相关。
Melanoma Res. 2019 Feb;29(1):30-37. doi: 10.1097/CMR.0000000000000515.
2
Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.原发性黑色素瘤及配对转移灶中BRAFV600突变的等位基因频率及其与转移性黑色素瘤BRAF抑制剂治疗的相关性。
Oncotarget. 2015 Nov 10;6(35):37895-905. doi: 10.18632/oncotarget.5634.
3
Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma.肿瘤内中性粒细胞和浆细胞样树突状细胞预示着不良预后,并与 AJCC Ⅰ/Ⅱ期黑色素瘤中 pSTAT3 的表达相关。
Cancer. 2012 May 1;118(9):2476-85. doi: 10.1002/cncr.26511. Epub 2011 Sep 22.
4
BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.原发性结节性黑色素瘤中BRAF-V600E的表达与侵袭性肿瘤特征及生存率降低相关。
Br J Cancer. 2016 Mar 29;114(7):801-8. doi: 10.1038/bjc.2016.44. Epub 2016 Feb 25.
5
BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.原发性皮肤恶性黑色素瘤及其配对转移灶中 BRAFV600E 蛋白的表达。
JAMA Dermatol. 2015 Apr;151(4):410-6. doi: 10.1001/jamadermatol.2014.3689.
6
Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.BRAF 蛋白在原发性黑色素瘤中的表达显著影响疾病进展和患者生存。
Br J Dermatol. 2013 Aug;169(2):320-8. doi: 10.1111/bjd.12351.
7
Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.BRAF(V600) 突变在转移性淋巴结切除术后黑色素瘤患者中的预后价值。
Ann Surg Oncol. 2012 Dec;19(13):4314-21. doi: 10.1245/s10434-012-2457-5. Epub 2012 Jul 7.
8
BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha.BRAF 突变状态可能对中剂量干扰素-α治疗的 III 期皮肤黑色素瘤的无病生存和总生存都有影响。
Cancer Chemother Pharmacol. 2019 Sep;84(3):521-526. doi: 10.1007/s00280-019-03842-1. Epub 2019 Apr 17.
9
The role of BRAF mutations in primary melanoma growth rate and survival.BRAF 突变在原发性黑色素瘤生长速度和存活率中的作用。
Br J Dermatol. 2015 Jul;173(1):76-82. doi: 10.1111/bjd.13756. Epub 2015 Jun 13.
10
Lymph node metastases of melanoma: challenges for BRAF mutation detection.黑色素瘤的淋巴结转移:BRAF 突变检测面临的挑战
Hum Pathol. 2015 Jan;46(1):113-9. doi: 10.1016/j.humpath.2014.09.014. Epub 2014 Oct 7.

引用本文的文献

1
Advancements and Challenges in Personalized Therapy for -Mutant Melanoma: A Comprehensive Review.- 突变型黑色素瘤个性化治疗的进展与挑战:综述
J Clin Med. 2024 Sep 12;13(18):5409. doi: 10.3390/jcm13185409.
2
Plasmacytoid dendritic cells at the forefront of anti-cancer immunity: rewiring strategies for tumor microenvironment remodeling.浆细胞样树突状细胞在抗肿瘤免疫的最前沿:重塑肿瘤微环境的重布线策略。
J Exp Clin Cancer Res. 2024 Jul 17;43(1):196. doi: 10.1186/s13046-024-03121-9.
3
Neutrophil Extracellular Traps Correlate with Tumor Necrosis and Size in Human Malignant Melanoma Metastases.
中性粒细胞胞外诱捕网与人类恶性黑色素瘤转移灶中的肿瘤坏死及大小相关。
Biology (Basel). 2023 Jun 6;12(6):822. doi: 10.3390/biology12060822.
4
Role of Single Nucleotide Polymorphism-Related Genes in Tumour Immune Cell Infiltration and Prognosis of Cutaneous Melanoma.单核苷酸多态性相关基因在肿瘤免疫细胞浸润和皮肤黑色素瘤预后中的作用。
Biomed Res Int. 2023 May 9;2023:3754094. doi: 10.1155/2023/3754094. eCollection 2023.
5
Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma.抑制髓过氧化物酶增强黑色素瘤的免疫检查点治疗。
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-005837.
6
Computer-Assisted Annotation of Digital H&E/SOX10 Dual Stains Generates High-Performing Convolutional Neural Network for Calculating Tumor Burden in H&E-Stained Cutaneous Melanoma.计算机辅助数字化 H&E/SOX10 双重染色标记生成高性能卷积神经网络,用于计算 H&E 染色皮肤黑色素瘤中的肿瘤负担。
Int J Environ Res Public Health. 2022 Nov 2;19(21):14327. doi: 10.3390/ijerph192114327.
7
The expression pattern of immune-related genes and characterization of tumor immune microenvironment: predicting prognosis and immunotherapeutic effects in cutaneous melanoma.免疫相关基因的表达模式与肿瘤免疫微环境特征:预测皮肤黑色素瘤的预后和免疫治疗效果。
World J Surg Oncol. 2022 Sep 22;20(1):303. doi: 10.1186/s12957-022-02767-z.
8
Expression Patterns of Necroptosis-Related Genes: Predicting Prognosis and Immunotherapeutic Effects in Cutaneous Melanoma.坏死性凋亡相关基因的表达模式:预测皮肤黑色素瘤的预后和免疫治疗效果
J Oncol. 2022 Jul 14;2022:5722599. doi: 10.1155/2022/5722599. eCollection 2022.
9
Characterization of the treatment-naive immune microenvironment in melanoma with mutation.黑色素瘤中 突变患者的治疗初治免疫微环境特征。
J Immunother Cancer. 2022 Apr;10(4). doi: 10.1136/jitc-2021-004095.
10
Genes Involved in Immune Reinduction May Constitute Biomarkers of Response for Metastatic Melanoma Patients Treated with Targeted Therapy.参与免疫再诱导的基因可能构成接受靶向治疗的转移性黑色素瘤患者反应的生物标志物。
Biomedicines. 2022 Jan 26;10(2):284. doi: 10.3390/biomedicines10020284.